Resveratrol, a red wine constituent, blocks the antimitogenic effects of estradiol on human female coronary artery smooth muscle cells

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages

  Dubey, Raghvendra K ^a,b,c   Jackson, Edwin K ^c   Gillespie, Delbert G ^c   Zacharia, Lefteris C ^c   Imthurn, Bruno ^a   Rosselli, Marinella ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 2 CHLORO 5 NITROBENZANILIDE; 2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; COLLAGEN; CYCLIN A; CYCLIN D; CYTOCHROME P450; DIARYLPROPIONITRILE; DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P27; RESVERATROL; ANTIMITOTIC AGENT; HORMONE ANTAGONIST; STILBENE DERIVATIVE;

ANTIMITOGENIC ACTIVITY; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; ESTROGEN METABOLISM; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROSOME; MITOGENICITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RED WINE; SMOOTH MUSCLE FIBER; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GROWTH, DEVELOPMENT AND AGING; METABOLISM; OSMOLARITY; PHYSIOLOGY; SEX DIFFERENCE; VASCULAR SMOOTH MUSCLE; VITIS; WINE;

ANTIMITOTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; FEMALE; HORMONE ANTAGONISTS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSMOLAR CONCENTRATION; SEX FACTORS; STILBENES; VITIS; WINE;

EID: 77956564992     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0460     Document Type: Article

References (30)

1. Renaud S, de Lorgeril M 1992 Wine, alcohol platelets, and the French paradox for coronary heart disease. Lancet 339:1523-1526
2. Saiko P, Szakmary A, Jaeger W, Szekeres T 2008 Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658:68-94
3. Dubey RK, Jackson EK 2001 Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol 280:F365-F388
4. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME 2002 Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092
5. Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B, Jackson EK 2003 CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension 41:807-813
6. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, Dubey RK 2003 Methoxyestradiols mediate the antimitogenic effects of 17β-estradiol. Direct evidence from catechol-O-methyltransferase knockout mice. Circulation 108:2974-2978
7. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK 2006 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 99:266-274
8. Dubey RK, Jackson EK 2001 Cardiovascular protective effects of 17β-estradiol metabolites. J Appl Physiol 91:1868-1883
9. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM 2000 Resveratrol acts as a mixed agonist/antagonist for estrogen receptor α and β. Endocrinology 141:3657-3667
10. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD 1999 Is resveratrol an estrogen agonist in growing rats ? Endocrinology 140:50-54
11. Lu R, Serrero G 1999 Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179:297-304
12. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ 2000 Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 66:769-777
13. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B, Keller PJ 2000 Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and MAP kinase activity. Arterioscler Thromb Vasc Biol 20:964-972
14. 2+ release from vascular smooth muscle cell microsomes. Exp Biol Med 227:36-44
15. Zacharia LC, Jackson EK, Gillespie DG, Dubey RK 2001 Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension 37:658-662
16. Brueggemeier RW, Tseng K, Katlic NE, Beleh MA, Lin YC 1990 Estrogen metabolism in primary kidney cell cultures from Syrian hamsters. J Steroid Biochem 36:325-331
17. Ulrich S, Loitsch SM, Rau O, von Knethen A, Brüne B, Schubert-Zsilavecz M, Stein JM 2006 Peroxisome proliferator-activated receptor-γ as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 66:7348-7354
18. Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL 1996 Resveratrol promotes atherosclerosis in hypercholesteromic rabbits. Life Sci 59:PL15-PL21
19. Soulat T, Philippe C, Bal dit Sollier C, Brézillon C, Berge N, Teissedre PL, Callebert J, Rabot S, Drouet L 2006 Wine constituents inhibit thrombosis but not atherogenesis in C57BL/6 apolipoprotein E-deficient mice. Br J Nutr 96:290-298
20. Noll C, Hamelet J, Ducros V, Belin N, Paul JL, Delabar JM, Janel N 2009 Resveratrol supplementation worsen the dysregulation of genes involved in hepatic lipid homeostasis observed in hyperhomocysteinemic mice. Food Chem Toxicol 47:230-236
21. Cignarella A, Minici C, Bolego C, Pinna C, Sanvito P, Gaion RM, Puglisi L 2006 Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. Nutr Metab Cardiovasc Dis 16:322-329
22. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE 2007 Phase 1 dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252
23. Park DW, Baek K, Kim JR, Lee JJ, Ryu SH, Chin BR, Baek SH 2009 Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 41:171-179
24. Poussier B, Cordova AC, Bacquemin JP, Sumpio BE 2005 Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg 42:1190-1197
25. Olson ER, Naugle JE, Zhang X, Bosmer JA, Meszaros JG 2005 Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 288:H1131-H1138
26. Li Y, Cao Z, Zhu H 2006 Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 53:6-15
27. Do GM, Kwon EY, Kim HJ, Jeon SM, Ha TY, Park T, Choi MS 2008 Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 374:55-59
28. Baur JA, Sinclair DA 2006 Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev 5:493-502
29. Alcaín FJ, Villaba JM 2009 Sirtuin activators. Expert Opin Ther Pat 19:403-414
30. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M 2009 Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74:619-624